Designing Cancer Vaccine against Lung Cancer

1690 Words4 Pages

Lung cancer is a leading cause of death worldwide both in men and women. It accounts for nearly 1.2 million deaths per year. Over the last few years many advances have been made in the field of surgery, chemotherapy and radiations for treating this deadly cancer but they are unlikely to result in cure. Lung cancer is associated with very bad prognosis. So there is a dire need of developing novel therapeutic vaccines for improving prognosis of this disease Cancer therapeutic vaccines are designed to regulate the host tumour interactions in order to shift the balance from tumour acceptance to tumour control. Therapeutic vaccine target tumour associated antigen including cancer testis antigens. KK-LC-1, antigenic peptide is used in a Multipeptide Vaccine to target Non-small cell lung carcinoma. KK-LC-1 is designated as Kita-kyushu lung cancer antigen 1. This antigen has been recently recognized and was found to be present in approximately 40 per cent of people suffering from lung adenocarcinoma. KK-LC-1 belongs to a family of Cancer testis antigens which are expressed in many cancerous tissues but are silent in normal tissue except testis. This antigen is specifically expressed in large proportion of lung cancer tissues and not in normal tissues except testis so it should be a potential target for immunotherapy. Use of KK-LC-1 antigenic peptide in peptide vaccine can prove to be useful in treating non-small cell lung carcinoma which accounts for 85% of lung cancers. Peptide vaccines specifically target single epitope. They are safe, non-toxic and easy to formulate. Apart from this peptide possess good tumour- penetrating ability and are biocompatible. Antigenic peptides are determined by using bioinformatics tools BLAST and syfpei... ... middle of paper ... ...al of Biomedicine and Biotechnology. 1-10. 4. Foon, KA et al. (2008). Cancer Vaccines: Activating the Immune System to Fight Cancer. Oncology issues. 5. Winter, H et al. (2011). Active-specific immunotherapy for non-small cell lung cancer. Journal of Thoracic Disease. 3 (2). 6. Thundimadathil, J. (2012). Cancer Treatment Using Peptides: Current Therapies and Future Prospects. Journal of Amino Acids. 2012, 1-13. 7. http://www.bio.davidson.edu/courses/immunology/Students/spring2000/wilson/interleukin12.html 8. http://www.rcsed.ac.uk/RCSEDBackIssues/journal/vol46_3/4630007.htm 9. http://www4.mpbio.com/ecom/docs/proddata.nsf/5f64ffd4f38c2fda8525645d00769d68/53d2a75653615bab852568cb00572ff3 10. http://www.mabtech.com/Main/Page.asp?PageId=16 11. http://dora.eeap.cwru.edu/vbv/cytokine-elispot-assays.html 12. http://www.invivogen.com/docs/Insight_200806.pdf Word count-1595

More about Designing Cancer Vaccine against Lung Cancer

Open Document